ArticleFrontiers in medicine2026
Pediatric lymphomatoid papulosis: a broad clinicopathologic spectrum including rare variants in a single-center case series.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lymphomatoid papulosis (LyP) is a rare CD30-positive cutaneous T-cell lymphoproliferative disorder, extremely uncommon in children and adolescents. Despite its indolent course, LyP may mimic malignant lymphomas clinically and histopathologically, making diagnosis challenging in pediatric patients. Objectives: To characterize the clinical, histopathologic, immunophenotypic and molecular features of pediatric LyP and to describe treatment approaches and clinical outcomes. Methods: We performed a retrospective observational study of pediatric patients with clinicopathologically confirmed LyP evaluated at our tertiary referral center between 2004 and 2025. Demographic, clinical, histopathologic, immunophenotypic, molecular, treatment and follow-up data were collected. Results: Nine patients were included (8 males, 1 female), with a median age at diagnosis of 11 years (range 2-18). Lesions predominantly involved the limbs (9/9, 100%), followed by the trunk (5/9, 56%) and hands (4/9, 44%). Ulceration or necrotic evolution occurred in 6/9 patients (67%). Type A was the most common histologic subtype (5/9, 56%), followed by single cases of types B, D, E and one overlap A-C case. CD30 expression was observed in all patients. T-cell receptor clonality was identified in 4/5 tested cases. Management was mainly conservative, consisting of topical corticosteroids and phototherapy (nbUVB or PUVA). Methotrexate was used in one patient. At the last follow-up, all patients were free of active LyP lesions, and no associated hematologic malignancy was documented. Conclusions: Pediatric LyP shows heterogeneous clinicopathologic features with overall favorable outcomes. However, long-term follow-up remains warranted due to the lifelong risk of associated lymphoproliferative disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.